Across TCGA pan-cancer cohorts, ADAT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAT2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ADAT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAT2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where ADAT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.918	0.543	.001	29	view →
HNSC	DFS	Median	III,IV	0.775	0.526	.022	9	view →
LUAD	OS	Quartile	All	0.876	0.572	.022	9	view →
PDAC	OS	Median	II,III,IV	0.323	0.711	.010	6	view →
GBM	OS	Quartile	All	0.736	0.381	.017	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ADAT2 tumor-vs-normal RNA expression · all ADAT2 data types